Loss of tyrosine hydroxylase expression within the nigro-striato-cortical pathways in the cirrhotic rat: The possible restorative effect of the neurosteroid dehydroepiandrosterone sulfate

Acta Histochemica

Volumn 115, Issue 6, 2013, Pages 637-645

  El Hiba, Omar ^a   Gamrani, Halima ^a   Chatoui, Hicham ^a   Ahboucha, Samir ^a  

^a FACULTÉ DES SCIENCES SEMLALIA   (Morocco)

Author keywords

Cirrhosis; Dehydroepiandrosterone sulfate; Rat; Substantia nigra pars compacta; Tyrosine hydroxylase; Ventral tegmental area

Indexed keywords

PRASTERONE SULFATE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CIRRHOSIS; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

CIRRHOSIS; DEHYDROEPIANDROSTERONE SULFATE; RAT; SUBSTANTIA NIGRA PARS COMPACTA; TYROSINE HYDROXYLASE; VENTRAL TEGMENTAL AREA;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; BRAIN DISEASES, METABOLIC; CEREBRAL CORTEX; CORPUS STRIATUM; DEHYDROEPIANDROSTERONE SULFATE; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

RATTUS;

EID: 84880330654     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.01.006     Document Type: Article

References (52)

1. Aldred S., Waring R.H. Localisation of dehydroepiandrosterone sulphotransferase in adult rat brain. Brain Res Bull 1999, 48:291-296.
2. Baulieu E.E., Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci USA 1998, 95:4089-4091.
3. Bergeron M., Swain M.S., Reader T.A., Butterworth R.F. Increased mesocortical dopaminergic function following ammonia administration to rats with portacaval anastomosis. Neurochem Res 1995, 10:79-86.
4. Bergqvist P.B., Vogels B.A., Bosman D.K., Maas M.A., Hjorth S., Chamuleau R.A., et al. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. J Neurochem 1995, 64::1238-1244.
5. Bergeron M., Reader T.A., Layrargues G.P., Butterworth R.F. Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res 1989, 14:853-859.
6. Björklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007, 30:194-202.
7. Butterworth R.F., Lalonde R., Power C., Baker G.B., Gamrani H., Ahboucha S. Dehydroepiandrosterone sulphate improves cholestasis-associated fatigue in bile duct ligated rats. Neurogastroenterol Motil 2009, 21:1319-1325.
8. Butterworth R.F., Norenberg M.D., Felipo V., Ferenci P., Albrecht J., Blei A.T. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009, 29:783-788.
9. Butterworth R.F. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis 2007, 22:309-320.
10. Butz M., Timmermann L., Braun M., Groiss S.J., Wojtecki L., Ostrowski S., et al. Motor impairment in liver cirrhosis without and with minimal hepatic encephalopathy. Acta Neurol Scand 2010, 122:27-35.
11. Compañy L., Zapater P., Pérez-Mateo M., Jover R. Extrapyramidal signs predict the development of overt hepatic encephalopathy in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2010, 22:519-525.
12. Charalampopoulos I., Alexaki V.I., Lazaridis I., Dermitzaki E., Avlonitis N., Tsatsanis C., et al. G protein-associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone. FASEB J 2006, 20:577-579.
13. Dillon J.S. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 2005, 4:377-385.
14. Dong Y., Benveniste E.N. Immune function of astrocytes. Glia 2001, 36:180-190.
15. El Hiba O., Gamrani H., Ahboucha S. Increased Reissner's fiber material in the subcommissural organ and ventricular area in bile duct ligated rats. Acta Histochem 2012, 114:673-681.
16. Erikson K.M., Dorman D.C., Lash L.H., Aschner M. Manganese inhalation by rhesus monkeys is associated with brain regional changes in biomarkers of neurotoxicity. Toxicol Sci 2007, 97:459-466.
17. Erazi H., Ahboucha S., Gamrani H. Chronic exposure to aluminum reduces tyrosine hydroxylase expression in the substantia nigra and locomotor performance in rats. Neurosci Lett 2011, 487:8-11.
18. Fan L.W., Tien L.T., Zheng B., Pang Y., Lin R.C., Simpson K.L., et al. Dopaminergic neuronal injury in the adult rat brain following neonatal exposure to lipopolysaccharide and the silent neurotoxicity. Brain Behav Immun 2011, 25:286-297.
19. Giguère J.F., Hamel E., Butterworth R.F. Increased densities of binding sites for the 'peripheral-type' benzodiazepine receptor ligand 3HPK11195 in rat brain following portacaval anastomosis. Brain Res 1992, 585:295-298.
20. Joebges E.M., Heidemann M., Schimke N., Hecker H., Ennen J.C., Weissenborn K. Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation. J Hepatol 2003, 38:273-280.
21. Lavoie J., Giguère J.-F., Layrargues G.P., Butterworth R.F. Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J Neurochem 1987, 49:692-697.
22. Lavoie J., Layrargues G.P., Butterworth R.F. Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 1990, 11:874-878.
23. Johnson D.A., Wu T., Li P., Maher T.J. The effect of steroid sulfatase inhibition on learning and spatial memory. Brain Res 2000, 865:286-290.
24. Liere P., Pianos A., Eychenne B., Cambourg A., Liu S., Griffiths W., et al. Novel lipoidal derivatives of pregnenolone and dehydroepiandrosterone and absence of their sulfated counterparts in rodent brain. J Lipid Res 2004, 45:2287-2302.
25. Luu-The V., Bernier F., Dufort I. Steroid sulfotransferases. J Endocrinol 1996, 150:S87-S97.
26. Lunzer M., James I.M., Weinman J., Sherlock S. Treatment of chronic hepatic encephalopathy with levodopa. Gut 1974, 15:555-561.
27. Michel H., Solere M., Granier P., Cauvet G., Bali J.P., Pons F., et al. Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial. Gastroenterology 1980, 79:207-211.
28. Montes S., Alcaraz-Zubeldia M., Muriel P., Ríos C. Striatal manganese accumulation induces changes in dopamine metabolism in the cirrhotic rat. Brain Res 2001, 891:123-129.
29. Morgan M.Y., Jakobovits A.W., James I.M., Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 1980, 78:663-670.
30. Mousseau D.D., Baker G.B., Butterworth R.F. Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. J Neurochem 1997, 68:1200-1208.
31. Mousseau D.D., Perney P., Layrargues G.P., Butterworth R.F. Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neurosci Lett 1993, 162:192-196.
32. Murray H.E., Gillies G.E. Differential effects of neuroactive steroids on somatostatin and dopamine secretion from primary hypothalamic cell cultures. J Neuroendocrinol 1997, 9:287-295.
33. Nawata H., Yanase T., Goto K., Okabe T., Ashida K. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mech Ageing Dev 2002, 123:1101-1106.
34. Reddy D.S., Kaur G., Kulkarni S.K. Sigma (sigma 1) receptor mediated antidepressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport 1998, 9:3069-3073.
35. Rao V.L., Audet R., Therrien G., Butterworth R.F. Tissue-specific alterations of binding sites for the peripheral-type benzodiazepine receptor ligand 3H-PK11195 in rats following portacaval anastomosis. Dig Dis Sci 1994, 39:1055-1063.
36. Record C.O., Buxton B., Chase R., Curzon G., Murray-Lyon I.M., Williams R. Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. Eur J Clin Invest 1976, 6:387-394.
37. Rose C., Butterworth R.F., Zayed J., Normandin L., Todd K., Michalak A., et al. Manganese deposition in basal ganglia structures results form both portal systemic shunting and liver dysfunction. Gastroenterology 1999, 117:640-644.
38. Spahr L., Vingerhoets F., Lazeyras F., Delavelle J., DuPasquier R., Giostra E., et al. Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis. Gastroenterology 2000, 119:774-781.
39. Steffensen S.C. Dehydroepiandrosterone sulfate suppresses hippocampal recurrent inhibition and synchronizes neuronal activity to theta rhythm. Hippocampus 1995, 5:320-328.
40. Svec F., Porter J.R. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 1998, 218:174-191.
41. Uribe M., García-Ramos G., Ramos M., Valverde C., Márquez M.A., Farca A., et al. Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy. Am J Gastroenterol 1983, 78:517-522.
42. Vilaplana J., Lavialle M. A method to quantify glial fibrillary acidic protein immunoreactivity on the suprachiasmatic nucleus. J Neurosci Methods 1999, 88:181-187.
43. Waśkiewicz J., Freśko I., Lenkiewicz A., Albrecht J. Reversible decrease of dopamine D2 receptor density in the striatum of rats with acute hepatic failure. Brain Res 2001, 900:143-145.
44. Watanabe Y., Kato A., Sawara K., Butterworth R.F., Sasaki T., Terasaki K., et al. Selective alterations of brain dopamine D(2) receptor binding in cirrhotic patients: results of a (11)C-N-methylspiperone PET study. Metab Brain Dis 2008, 23:265-274.
45. Wolkowitz O.M., Reus V.I., Roberts E., Manfredi F., Chan T., Raum W.J., et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997, 41:311-318.
46. Wolkowitz O.M., Reus V.I., Keebler A., Nelson N., Friedland M., Brizendine L., et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999, 156:646-649.
47. Wright G., Davies N.A., Shawcross D.L., Hodges S.J., Zwingmann C., Brooks H.F., et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 2007, 45:1517-1526.
48. Yen S.S. Dehydroepiandrosterone sulfate and longevity: new clues for an old friend. Proc Natl Acad Sci USA 2001, 98:8167-8169.
49. Young S.N., Lal S., Feldmuller F., Aranoff A., Martin J.B. Relationships between tryptophan in serum and CSF and 5-hydroxyindoleacetic acid in CSF of man: effects of cirrhosis of the liver and probenecid administration. J Neurol Neurosurg Psychiatry 1975, 38:322-330.
50. Zeneroli M.L., Baraldi M., Ventura E., Vezzelli C., Tofanetti O., Germini M., et al. Alterations of GABA-A and dopamine D-2 brain receptors in dogs with portal-systemic encephalopathy. Life Sci 1991, 48:37-50.
51. Zhang D., Kanthasamy A., Anantharam V., Kanthasamy A. Effects of manganese on tyrosine hydroxylase (TH) activity and TH-phosphorylation in a dopaminergic neural cell line. Toxicol Appl Pharmacol 2011, 254:65-71.
52. Zhang P., Wong T.A., Lokuta K.M., Turner D.E., Vujisic K., Liu B. Microglia enhance manganese chloride-induced dopaminergic neurodegeneration: role of free radical generation. Exp Neurol 2009, 217:219-230.